Currently out of the existing stock ratings of Matthew Taylor, 126 are a BUY (61.76%), 60 are a HOLD (29.41%), 18 are a SELL (8.82%).

Matthew Taylor

Work Performance Price Targets & Ratings Chart

Analyst Matthew Taylor, currently employed at JEFFERIES, carries an average stock price target met ratio of 67.54% that have a potential upside of 17.68% achieved within 166 days.

Matthew Taylor’s has documented 386 price targets and ratings displayed on 34 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NVRO, Nevro Corp at 10-Feb-2025.

Wall Street Analyst Matthew Taylor

Analyst best performing recommendations are on TNDM (TANDEM DIABETES CARE).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 11/27/2018. The price target of $36 was fulfilled within 2 days with a profit of $2.71 (8.14%) receiving and performance score of 40.7.

Average potential price target upside

of $44.95 (18.27%) on SYK (STRYKER).
of $37.01 (22.97%) on PODD (INSULET).
of $36.16 (17.73%) on TFX (TELEFLEX).

ABT Abbott Laboratories BAX Baxter International BDX Becton Dickinson and Company DXCM DexCom EW Edwards Lifesciences Corp GMED Globus Medical INMD InMode Ltd ISRG Intuitive Surgical MASI Masimo MDT Medtronic PLC NUVA NuVasive PHG Koninklijke Philips NV ADR TFX Teleflex UTRS Minerva Surgical VAR Varian Medical Systems LIVN LivaNova PLC PODD Insulet RMD ResMed IART Integra LifeSciences Holdings NVRO Nevro Corp TNDM Tandem Diabetes Care ZBH Zimmer Biomet Holdings SYK Stryker ATEC Alphatec Holdings BSX Boston Scientific Corp AXNX Axonics Modulation Technologies PEN Penumbra CNMD CONMED HRC Hill-Rom Holdings ESTA Establishment Labs Holdings SENS Senseonics Holdings SIBN Si-Bone VREX Varex Imaging Corp NARI Inari Medical

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Matt Miksic (BARCLAYS)